Text Size

A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
BrainCells Inc.
ClinicalTrials.gov Identifier:
NCT01546051
First received: February 24, 2012
Last updated: March 6, 2012
Last verified: March 2012
History of Changes

February 24, 2012
March 6, 2012
October 2011
January 2012   (final data collection date for primary outcome measure)
Safety [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Safety will be evaluated by adverse events, vital signs, ECG, clinical labs, and physical exam.
Same as current
Complete list of historical versions of study NCT01546051 on ClinicalTrials.gov Archive Site
Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632 [ Time Frame: predose and at specified intervals up to 72 hours post-dose ] [ Designated as safety issue: No ]
The pharmacokinetics of BCI-838 and its metabolite BCI-632, an assessment of the dose proportionality of the pharmacokinetics following single ascending doses of BCI-838, and an evaluation of the relative bioavailability and pharmacokinetics of the metabolite BCI-632 following oral administration of several new pro-drug candidates will be completed by assessment of Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel.
Same as current
Not Provided
Not Provided
 
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects

This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.

The first phase of this study will evaluate the safety and tolerability of BCI-838 following oral administration of single doses of BCI-838 in healthy male subjects. The pharmacokinetics of BCI-838 and its metabolite BCI-632 following single ascending doses of BCI-838 will be evaluated, as will the effect of food on the pharmacokinetics of BCI-838 and its metabolite following single oral doses of BCI-838 in healthy male subjects.

The second phase of this study will evaluate and compare the relative bioavailability and PK of the metabolite BCI-632 following single oral administration of several new pro-drug candidates in healthy male subjects.
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Healthy
  • Drug: BCI-838
    BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
  • Drug: BCI-838
    BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
  • Drug: BCI-1038, BCI-1206 & BCI-1283
    Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
  • Drug: BCI-838
    BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
  • Experimental: BCI-838 Food Effect Dosing Arm 1
    Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
    Intervention: Drug: BCI-838
  • Experimental: BCI-838 Fasted Dosing (100 & 300 mg)
    Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
    Intervention: Drug: BCI-838
  • Experimental: BCI-1038, BCI-1206 & BCI-1283
    Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
    Intervention: Drug: BCI-1038, BCI-1206 & BCI-1283
  • Experimental: BCI-838 Fasted Dosing (900 mg)
    Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
    Intervention: Drug: BCI-838
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
February 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult male healthy volunteer, 18-55 years of age
  • Body Mass Index (BMI) between 18.0 to 30.0 kg/m2 inclusive
  • Good general health as determined by medical history and physical examination with no clinically significant medical findings and no clinically relevant medical or surgical history and no acute or ongoing conditions within the past 30 days
  • Able to participate and willing to give written informed consent and to comply with the study restrictions

Exclusion Criteria:

  • Clinically significant medical abnormality, chronic disease or history or presence of significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or neurological disorder
  • History or current use of alcohol abuse or drug addiction
  • Participation in a drug study within 60 days prior to drug administration.
  • Participation in more than 3 other drug studies in the 10 months preceding the start of this study
  • Donation or blood loss of more than 50 mL of blood within 60 days prior to the first drug administration. Donation of more than 1.5 liters of blood in the 10 months preceding the start of this study
  • Illness within 5 days prior to drug administration
Male
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01546051
BCI-632-CL-002
No
BrainCells Inc.
BrainCells Inc.
Not Provided
Principal Investigator: Principal Investigator PRA International
BrainCells Inc.
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP